Are INDP insiders buying or selling?

In the last 90 days, Indaptus (INDP) had 9 insider transactions. Track every executive trade, dollar amount, and date.

Which hedge funds own INDP?

See every hedge fund and asset manager holding Indaptus (INDP).

How much of INDP trades in dark pools?

Track Indaptus (INDP) dark pool activity and off-exchange block trades.

Indaptus (INDP) — Beat EPS 15 of Last 16 Quarters

$1.29

-0.04 (-3.01%)

Weekly Expected Move ±14.8%

$1 $1 $2 $2 $2

NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 34 · $2.3M mcap · 1M float · 3.87% daily turnover · Short 36% of daily vol

Smart Money Score

No convergence signal

Key Statistics

Market Cap$2.3M

52W Range1.33-19.908

Volume43,088

Avg Volume55,109

Beta1.37

Dividend—

Analyst Ratings

2 Buy 0 Hold 0 Sell

Consensus Buy

Company Info

CEOJunyi Dai

Employees7

SectorHealthcare

IndustryBiotechnology

IPO Date2015-08-04

Websiteindaptusrx.com

3 Columbus Circle
New York City, NY 10019
US

347 480 9760

About Indaptus Therapeutics, Inc.

Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.

Latest News

Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewsWire-EarningsResults · 5d ago

Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Benzinga-Earnings · 5d ago